With pos­i­tive PhI­II da­ta, Mer­ck sets up a block­buster at­tempt to over­throw Pfiz­er's reign­ing Pre­vnar 13

Mer­ck is near­ing the end of a years-long ef­fort to de­throne Pfiz­er’s megablock­buster pneu­mo­coc­cal con­ju­gate vac­cine, Pre­vnar 13.

Stray­ing away from its cash cow Keytru­da, the NJ-based biotech says it will ap­ply to li­cense its can­di­date V114, which beats Pre­vnar by two pneu­mo­coc­cus strains, by the end of this year. The ex­per­i­men­tal vac­cine met its pri­ma­ry im­muno­genic­i­ty ob­jec­tives in two Phase III stud­ies, ac­cord­ing to Mer­ck $MRK.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.